Search
pozelimab-bbfg (Veopoz)
Indications:
- treatment of adult & pediatric patients >=1 year of age with CD55-deficient protein-losing enteropathy (CHAPLE disease)
Contraindications:
- unresolved Neisseria meningitidis infection
- interrupt treatment with VEOPOZ in patients with serious encapsulated bacterial infection
Dosage:
- initial dose 30 mg/kg IV followed by weekly 10 mg/kg SC doses
- may increase to 12 mg/kg SC
- maximum daily dose: 800 mg
Adverse effects:
- most common:
- upper respiratory tract infection
- fracture
- urticaria
- alopecia
Mechanism of action:
- human monoclonal IgG4 directed against the terminal complement protein C5
- blocks cleavage of C5 to C5a (anaphylatoxin) & C5b, thus blocking formation of the membrane-attack complex (C5b-C9) thus inhibiting cell lysis
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- U.S Food & Drug Administration, Aug 18, 2023
FDA approves first treatment for CD55-deficient protein-losing enteropathy
(CHAPLE disease)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease
- Highlights of Prescribing Information
VEOPOZ (pozelimab-bbfg) injection, for intravenous or subcutaneous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf